March Sales at Wholly-Owned Subsidiary Mesa Pharmacy exceed $8.8M.

John Garbino and Ed Kurtz Join Board of Directors
Name change imminent.
 
PALO ALTO, CA, April 9, 2014 -- The PAWS Pet Company, Inc. (OTCQB: PAWS), announced it completed the merger of Pharmacy Development Corp. (PDC), the parent company of MESA Pharmacy, Inc. (“Mesa”) into PDC, Inc. (PDCINC), PAWS wholly-owned subsidiary on March 31, 2014.
 

Mesa Pharmacy prescription orders for February exceed $7.4 million. Sales continue to increase in line with expectations.

PALO ALTO, CA, March 12, 2014  - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that revised February orders at its Mesa Pharmacy, Inc. (Mesa) subsidiary generated gross revenues, excluding allowances for returns and discounts, exceeding $7.4 Million Dollars.  Prescription orders for transdermal topical pain medications continue to rise. 
 

Mesa Pharmacy prescription orders for February exceed $6.5 million. Sales continue to increase inline with expectations.

IRVINE, CA, Feb. 26, 2014  - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that February orders at its Mesa Pharmacy, Inc. (Mesa) subsidiary have continued to increase inline with expectations and have generated gross revenues, excluding allowances for returns and discounts, exceeding $6.5 Million Dollars.  "We are currently filling prescriptions for transdermal topical pain medications of approximately $400,000 dollars per day".  Stated Andrew Do, Mesa's President and Registered Pharmacist.

PAWS subsidiary Mesa Pharmacy executes marketing agreement

SHOWS STRONG SALES IN JANUARY AND CONTINUED GROWTH IN FEBRUARY.

IRVINE, CA, Feb. 19, 2014  - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that Mesa Pharmacy Inc. ("Mesa") has executed a marketing agreement with Trestles Pain Specialists LLC of San Juan Capistrano, California to expand sales within California and, eventually, in other states.  Physician groups and industrial medical clinics in the central valley of California and other new locations throughout California will now be using the alternative transdermal medications Mesa compounds.

Mesa Pharmacy's Sales exceed $3,600,000 in November. Audit Nearly Complete. Acquisition May Be Completed Soon

FDA Reclassification of Hydrocodone to Schedule II Could Boost Sales.

PALO ALTO, CA, Dec. 5, 2013 - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that work on the name change to Praxsyn Corporation is nearing completion and that the Company expects to be able to file a request with FINRA early next week along with filing the necessary filings and disclosures with the SEC and the State of Illinois.

Pages